-
-
-
-
-
-
-
Citi Opens 90-Day Upside Catalyst Watch on Ideaya Biosciences (IDYA)
-
-
-
-
-
-
-
Citizens Reiterates Market Outperform on Ideaya Biosciences (IDYA); Bullish on Darovasertib
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Ideaya Biosciences (IDYA)
-
-
-
-
-
-
-
IDEAYA Biosciences submits IND for PRMT5 inhibitor IDE892
-
-
-
-
-
-
-
TD Cowen Starts Ideaya Biosciences (IDYA) at Buy
-
-
-
-
-
-
-
IDEAYA Biosciences (IDYA) Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma
-
-
-
-
-
-
-
RBC report: Biotech faces both uncertainty and growth opportunities in 2025
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

